PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Azathioprine - Rheumatology indications
PAD Profile : Azathioprine - Rheumatology indications
Keywords :
RMOC, national shared care, Polyarteritis Nodosa, Polymyositis, Rheumatoid Arthritis, Systemic lupus erythematosus, SLE, inflammatory arthritis (off label indication), connective tissue disease(off label indication), Vasculitis (off label indication), giant cell arteritis (off label indication)
Brand Names Include :
Imuran
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Inflammatory bowel disease
- Hepatology Indications
- Haematology Indications
- Dermatology indications
- Uveitis
- Respiratory disease indications
- Renal indications
- Oral disease indications
- Neurology indications
- Scleritis
- Transplantation
Additional Documents
Type
Document
Review Date
Shared Care
Shared Care
01 January 2025
Shared Care
Committee Recommendations
Date
Committee Name
Narrative
05 October 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol for azathioprine and mercaptopurine for patients in adult services (non- transplant indications)
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.01. Antiproliferative immunosuppressants